Research Topics
| Eileen ReganSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumorsJennifer A Chan
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
Cancer Chemother Pharmacol 71:1241-6. 2013..Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET...- Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan
Dana Farber Cancer Institute, Boston, MA 02215, USA
J Clin Oncol 30:2963-8. 2012..We performed a phase II study to evaluate the efficacy of temozolomide in combination with bevacizumab in patients with locally advanced or metastatic NETs... 
Hormone replacement therapy and survival after colorectal cancer diagnosisJennifer A Chan
Dana Farber Cancer Institute, Dana 1220, Boston, MA 02115, USA
J Clin Oncol 24:5680-6. 2006..Postmenopausal estrogen use has been shown to decrease the incidence of colorectal cancer, but there is limited information regarding the effect of estrogen use on survival after diagnosis of colorectal cancer...- Emerging therapies for the treatment of patients with advanced neuroendocrine tumorsJennifer A Chan
Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
Expert Opin Emerg Drugs 12:253-70. 2007..Ongoing randomized studies should help better define the role these agents will play in the future treatment of patients with this disease... - Association of family history with cancer recurrence and survival among patients with stage III colon cancerJennifer A Chan
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
JAMA 299:2515-23. 2008..However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain... - Progress in the treatment of neuroendocrine tumorsJennifer A Chan
Gastrointestinal Cancer Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Oncol Rep 11:193-9. 2009..Additionally, agents targeting the vascular endothelial growth factor pathway and mammalian target of rapamycin have shown preliminary evidence of activity and are currently being evaluated in large randomized studies... - Phase II study of pemetrexed in patients with advanced neuroendocrine tumorsJennifer A Chan
Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA
Cancer Chemother Pharmacol 66:961-8. 2010..Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors... 
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinomaJ A Chan
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Ann Oncol 22:1367-73. 2011..We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma...- New treatment options for patients with advanced neuroendocrine tumorsJennifer A Chan
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Curr Treat Options Oncol 12:136-48. 2011..Future studies will likely further define the role of these agents in the advanced carcinoid patient population... - A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumorsMatthew H Kulke
Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Chemother Pharmacol 68:293-300. 2011..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors... - Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS ONE 7:e38231. 2012..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer... - Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu
Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
Cancer Chemother Pharmacol 59:285-93. 2007.... - Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
Clin Cancer Res 19:1557-66. 2013..We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)...